Russell Investments Group Ltd. Trims Stake in Intuitive Surgical, Inc. $ISRG

by · The Cerbat Gem

Russell Investments Group Ltd. decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) by 1.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 367,375 shares of the medical equipment provider’s stock after selling 7,127 shares during the period. Russell Investments Group Ltd. owned approximately 0.10% of Intuitive Surgical worth $199,429,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of ISRG. Nuveen LLC bought a new stake in Intuitive Surgical during the first quarter valued at approximately $1,715,899,000. Vanguard Group Inc. grew its position in Intuitive Surgical by 2.1% in the second quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock worth $18,115,025,000 after acquiring an additional 670,302 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Intuitive Surgical by 26.1% in the first quarter. Goldman Sachs Group Inc. now owns 2,819,666 shares of the medical equipment provider’s stock valued at $1,396,496,000 after acquiring an additional 584,375 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Intuitive Surgical by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,393,951 shares of the medical equipment provider’s stock worth $1,680,922,000 after purchasing an additional 566,979 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in Intuitive Surgical by 20.4% during the second quarter. Jennison Associates LLC now owns 3,122,390 shares of the medical equipment provider’s stock worth $1,696,738,000 after purchasing an additional 528,359 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $578.87 on Wednesday. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The company’s 50-day simple moving average is $497.66 and its 200 day simple moving average is $504.41. The firm has a market capitalization of $207.51 billion, a P/E ratio of 76.57, a PEG ratio of 4.94 and a beta of 1.62.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The company had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the company earned $1.84 EPS. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Leerink Partners lifted their price target on shares of Intuitive Surgical from $593.00 to $600.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 22nd. Jefferies Financial Group raised their price objective on Intuitive Surgical from $550.00 to $560.00 and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Truist Financial set a $620.00 price objective on Intuitive Surgical and gave the company a “buy” rating in a research note on Wednesday, October 22nd. The Goldman Sachs Group lifted their target price on shares of Intuitive Surgical from $567.00 to $621.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Finally, HSBC raised their price target on shares of Intuitive Surgical from $595.00 to $644.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $608.92.

View Our Latest Stock Analysis on Intuitive Surgical

Insiders Place Their Bets

In other news, CEO David J. Rosa sold 24,500 shares of the company’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $547.55, for a total value of $13,414,975.00. Following the transaction, the chief executive officer owned 234,256 shares in the company, valued at approximately $128,266,872.80. This represents a 9.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Brian Edward Miller sold 3,500 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $575.00, for a total transaction of $2,012,500.00. Following the completion of the transaction, the executive vice president owned 5,758 shares of the company’s stock, valued at approximately $3,310,850. The trade was a 37.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 116,164 shares of company stock valued at $61,916,172. 0.70% of the stock is owned by company insiders.

Intuitive Surgical Profile

(Free Report)

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

Further Reading